Certara, Inc. (CERT) stock intrinsic value fair value estimate & owner earnings analysis

Certara is a biosimulation company: it sells software (and related subscriptions/licenses) and provides consulting services that help pharmaceutical and biotech companies use computer modeling -- rather than only physical trials -- to design drugs, predict how they behave in the body, and support regulatory submissions to agencies like the FDA. This approach, known in the industry as model-informed drug development, is now a well-established part of how new drugs are approved, and Certara is a market leader in providing the software and expertise for it. The business has two halves. Software (licenses and subscriptions) is now about 44% of revenue and has grown roughly 18% a year for the last two years; services (regulatory and consulting work) is the other 56% and has grown only about 3% a year. Software is the more valuable half: it is higher-margin and stickier. Some of the recent software growth came from acquisitions (Certara bought Formedix and Applied BioMath in late 2023 and Chemaxon, a chemistry software maker, in October 2024), so the organic growth rate is somewhat lower than the reported growth rate -- a distinction we built into the assumptions below rather than simply extrapolating recent results. No acquisitions closed in 2025, giving a cleaner read on the underlying business that year. Customer concentration is low and improving: no single customer is more than 10% of revenue, and the top ten customers together fell from 27% to 24% of revenue. The company spends heavily to build its software platform -- capitalized software development spending has grown from about 3% of revenue in 2021 to over 6% in 2025 -- which is a real cost of staying competitive, and we treated it as such rather than as a one-time or optional expense. Because of this rising investment, cash earnings available to owners have grown much more slowly (about 3-4% a year recently) than revenue (about 9% a year), even though the underlying business is healthy. Stock-based compensation, a real cost to shareholders through dilution, runs at roughly 8% of revenue and was fully deducted in our figures. In 2023 Certara wrote off $47 million of goodwill and recorded a $24 million charge related to an acquisition earn-out -- both non-cash, but both signs that some past acquisitions were paid for too optimistically. That history of occasional overpaying for deals is a real risk and is reflected in our more cautious (bear-case) growth assumptions, though it is not severe enough on its own to change the investment thesis. We valued the underlying business (before its debt) under three scenarios and then subtracted what the company owes. In the bear case, we assumed revenue and cash-earnings growth essentially stalls -- a plausible outcome if disruptions to government-funded biomedical research (which the company has flagged as a live risk from recent federal funding actions) or increased competition slow customer spending, combined with continued heavy platform investment. The base case assumes growth continues but decelerates in a pattern consistent with the last two years, moderating over the next decade. The bull case credits a few more years of the software segment's demonstrated double-digit growth before it, too, slows, plus some improvement in cash-earnings growth as the heavy investment in the software platform matures. In all three cases, we did not assume growth continues indefinitely past ten years without a specific reason; we instead assumed the business simply continues at whatever level it has reached by then, since biosimulation's role in drug development is well established but we have no specific evidence of it continuing to expand forever. On debt: Certara carries about $293 million of term-loan borrowings (recently refinanced out to 2031, so there is no near-term refinancing pressure) against about $189 million of cash, for net debt of roughly $104 million. The loan's current interest cost (about 7.3%) runs somewhat above the discount rate we use to value all businesses in this analysis, so we increased the debt figure modestly to reflect that extra cost over the loan's remaining life. After this adjustment, net debt reduces the per-share value of the business by roughly $0.74. The business generates several times its interest bill in cash each year, so debt service is not a near-term concern in any of the three cases. Putting this together: we estimate the shares are worth roughly $6 in the bear case, $9 in the base case, and $12 in the bull case. Given the business's real but moderate risks (rising platform-investment spending, some acquisition-integration history, and exposure to research-funding policy), the margin-of-safety price is set meaningfully below our base-case estimate.